The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Discovery of targetable mutational signatures in advanced prostate cancer (aPC) using machine learning and next-generation sequencing (NGS) of circulating tumor DNA (ctDNA).
 
Edwin Lin
No Relationships to Disclose
 
Andrew W Hahn
No Relationships to Disclose
 
Guru Sonpavde
Honoraria - UpToDate
Consulting or Advisory Role - Agensys; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genentech; Janssen; Merck; Novartis; Sanofi
Speakers' Bureau - Clinical Care Options/NCCN; Onclive; Physicans' Education Resource; Research to Practice
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Janssen (Inst); Merck (Inst); Onyx (Inst); Pfizer (Inst); Sanofi (Inst)
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Boehringer Ingelheim; Bristol-Myers Squibb
 
Michael B. Lilly
Research Funding - Bavarian Nordic (Inst)
 
Roberto Nussenzveig
No Relationships to Disclose
 
Elisa Ledet
No Relationships to Disclose
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Petros Grivas
Consulting or Advisory Role - AstraZeneca; Biocept; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Exelixis; Foundation Medicine; Genentech; Merck; Pfizer; QED Therapeutics; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Genentech
Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncogenex (Inst); Pfizer (Inst)
 
Thereasa A. Rich
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Victoria M. Raymond
Employment - Guardant Health; Trovagene
Stock and Other Ownership Interests - Guardant Health; Trovagene
 
A. Oliver Sartor
Stock and Other Ownership Interests - GlaxoSmithKline; Lilly; Noria Pharma Solutions
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; Bristol-Myers Squibb; Celgene; Constellation Pharmaceuticals; Dendreon; EMD Serono; Endocyte; Johnson & Johnson; Oncogenex; Pfizer; Progenics; Sanofi
Research Funding - Bayer (Inst); Endocyte (Inst); Innocrin Pharma (Inst); InVitae (Inst); Johnson & Johnson (Inst); Merck; Sanofi (Inst)
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Johnson & Johnson; Progenics; Sanofi
 
Mark Yandell
No Relationships to Disclose
 
Neeraj Agarwal
Consulting or Advisory Role - Argos Therapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EMD Serono; Exelixis; Foundation One Inc; Genentech/Roche; Lilly; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Medivation (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Takeda (Inst); TRACON Pharma (Inst)